Breast Cancer SurvivorshipWeCan-RuralNCT07426952
Weight Management After Cancer for Survivors in Rural Communities
A study testing WeCan-Rural Program in people with Breast Cancer Survivorship and Weight Management, run by Duke University at 5 sites in United States.
Trial summary
This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight. These changes may help lower the risk of heart disease after cancer treatment. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer Survivorship, Weight Management, Cardiovascular (CV) Risk
- What is being tested?
- WeCan-Rural Program
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 5 sitesUnited States
- Study dates
- 31 Aug 2026to 31 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- aged 18 years or older
- female (biological sex)
- diagnosis of stage I-III breast cancer
- completed treatments with curative intent (with the exception of hormonal treatments) in the last 5 years
- body mass index >30
- healthy enough to participate in home-based physical activity
- able to speak/read English
- reports rating of ≥4 (i.e., moderate or more severe) out of 10 for one or more of the following symptoms at its worst in the last month (per the MD Anderson Symptom Inventory): pain, fatigue, sadness, and/or distress
Who cannot join
- visual, hearing or cognitive impairment or severe mental illness interfering with participation
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Recruiting
Duke University Medical Center
Durham, North Carolina, 27705
Smrithi Divakaran, MPH, 919-681-7695, smrithi.divakaran@duke.edu
Caroline Dorfman, PhD, 919-416-3473, caroline.dorfman@duke.edu
- Recruiting
Maria Parham Cancer Center
Henderson, North Carolina, 27536
Smrithi Divakaran, MPH, 919-681-7695, smrithi.divakaran@duke.edu
Caroline Dorfman, PhD, 919-416-3473, caroline.dorfman@duke.edu
- Recruiting
Scotland Health
Laurinburg, North Carolina, 28352
Smrithi Divakaran, MPH, 919-681-7695, smrithi.divakaran@duke.edu
Caroline Dorfman, PhD, 919-416-3473, caroline.dorfman@duke.edu
- Recruiting
UNC Health Southeastern
Lumberton, North Carolina, 28358
Smrithi Divakaran, MPH, 919-681-7695, smrithi.divakaran@duke.edu
Caroline Dorfman, PhD, 919-416-3473, caroline.dorfman@duke.edu
- Recruiting
UNC Health Johnston
Smithfield, North Carolina, 27577
Smrithi Divakaran, MPH, 919-681-7695, smrithi.divakaran@duke.edu
Caroline Dorfman, PhD, 919-416-3473, caroline.dorfman@duke.edu
About this study
Official title: Development and Pilot Testing of a Novel Intervention to Reduce Cardiovascular Disease Risk Among Breast Cancer Survivors Living in Rural, Medically Underserved Communities
This study is testing a new program called WeCan-Rural, designed to help breast cancer survivors manage symptoms and build healthy habits like eating well, staying active, and managing their weight. These changes may help lower the risk of heart disease after cancer treatment.
The study will answer two main questions:
Read more
- Can study team successfully recruit and keep participants in the study, and will the participants find the program helpful and easy to follow?
- Will participants who join the program see better results in areas like weight, symptoms, diet, physical activity, and confidence in managing the participant's health compared to those who receive standard care?
Here's what participants will do:
- Visit the participant's clinic twice (about 12 weeks apart) to be weighed, have the blood pressure checked, give a blood sample, and complete a short walking test
- Fill out online surveys about the participant's health, diet, physical activity, symptoms, and confidence in managing the participant's health
- Be randomly assigned (like flipping a coin) to either receive the WeCan-Rural program or standard health information
- If assigned to the program, attend 12 weekly one-hour video sessions on Zoom with a trained therapist
Read the detailed description
Breast cancer survivors often face long-term health challenges after treatment, including a higher risk of heart disease. This risk is especially high for women living in rural areas, where access to healthcare and healthy food may be limited, and opportunities for physical activity may be harder to find. Many survivors also deal with ongoing symptoms like pain, fatigue, and emotional distress, which can make it harder to eat well, stay active, and manage their weight.
This study will test a program called WeCan-Rural, designed to help breast cancer survivors improve their health and lower their risk of heart disease. The program teaches skills for healthy eating, physical activity, and managing symptoms that can get in the way of a healthy lifestyle. It includes 12 weekly sessions delivered remotely through Zoom, so participants can join from home. Each session lasts about an hour and covers topics like nutrition, exercise, and ways to cope with symptoms using strategies like relaxation and pacing.
Participants will receive tools to help them track their progress, including a wireless activity tracker, a scale, and a blood pressure monitor. They'll also get printed materials and access to online videos showing how to do recommended exercises. If needed, participants will be provided with a tablet and data plan to make sure they can join the sessions.
The study will include 40 breast cancer survivors who have completed treatment and are living in rural, medically underserved areas. Half will receive the WeCan-Rural program, and half will receive standard health information from the National Cancer Institute. Researchers will look at how easy it is to recruit and keep participants in the program, how satisfied participants are with it, and whether it helps improve the participant's weight, symptoms, diet, physical activity, and confidence in managing the participant's health. The study will also measure changes in heart health indicators like blood pressure, cholesterol, and blood sugar.
If the program is found to be helpful and well-received, it may be tested in a larger study in the future.
- Being tested
- WeCan-Rural Program
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WeCan-Rural ProgramBehavioural
The WeCan-Rural program includes 12, one-hour weekly sessions via Zoom that help breast cancer survivors manage symptoms like pain, fatigue, and emotional distress, while also building healthy habits around eating, exercise, and weight management.
| Study group | Role | What they receive |
|---|---|---|
| WeCan-Rural | Experimental | Participants will receive the WeCan-Rural intervention, which includes twelve sessions delivered remotely (i.e., videoconferencing) by a trained therapist. Receives: Behavioral: WeCan-Rural Program |
| Control | No intervention | Participants will receive the National Cancer Institute-developed booklet "Facing Forward: Life After Cancer Treatment," which presents information about cancer survivorship topics. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Satisfaction with Treatment and Interventionist as measured by the Satisfaction with Therapy and Therapist Scale-Revised (STTS-R)
Participants will complete the 13-item Satisfaction with Therapy and Therapist Scale-Revised specific to the program they received. The first 12 items ask participants to rate their agreement with statements related to intervention satisfaction on a 5-point scale ranging from "strongly disagree" (1) to "strongly agree" (5). The 13th item asks "How much did the intervention help with your symptoms?" with 5 answer choices ranging from "made things a lot better" to "made things a lot worse."
Measured: Post-treatment (about 12-14 weeks after baseline)
Acceptability as measured by the Treatment Acceptability Questionnaire
The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective. Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable") and averaged.
Measured: Post-treatment (about 12-14 weeks after baseline)
Secondary outcomes (19)
Change in blood pressure (systolic and diastolic)
Both systolic and diastolic blood pressure will be assessed at the baseline and follow-up assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in weight
Participants will be weighed at each assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in total cholesterol
Cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in LDL cholesterol
LDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in HDL cholesterol
HDL cholesterol will be assessed through peripheral blood at the baseline and follow-up assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in hemoglobin A1c
Hemoglobin A1c will be assessed through peripheral blood at the baseline and follow-up assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in C-reactive protein
C-reactive protein will be assessed through peripheral blood at the baseline and follow-up assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in high sensitivity troponin
High sensitivity troponin will be assessed through peripheral blood at the baseline and follow-up assessment.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Change in aerobic capacity and endurance as measured by the 6-Minute Walk Test
The 6-minute walk test is a self-paced, timed test of the total distance in meters that a patient is able to walk over a six-minute period and assesses the ability to exert effort during activity. Higher values indicate higher aerobic capacity and endurance.
Measured: From Baseline to Post-treatment (about 12-14 weeks after baseline)
Pain severity and interference as measured by the Brief Pain Inventory
The Brief Pain Inventory will be used to assess pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). This measures includes a body map on which the patient can mark the location(s) in which they are experiencing pain, as well as 8 questions on a scale of 0 to 10 with higher scores indicating worse pain severity or pain interference.
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Emotional distress as measured by PROMIS Depression Short Form
Depressive symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form, an 8-item measure assessing symptoms of depression in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Emotional distress as measured by PROMIS Anxiety Short Form
Symptoms of Anxiety will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form, an 8-item measure assessing symptoms of anxiety in the last week. Responses are on a 5-point scale from "never" (1) to "always" (5).
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Fatigue as measured by PROMIS Fatigue Scale
Fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, a 6-item self-report measure of fatigue. Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"), providing ratings on a scale from "not at all" (1) to "very much" (5).
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Diet as measured by the Dietary Screener Questionnaire
The Dietary Screener Questionnaire is a 25-item measure asking participants to rate on the frequency of eating/drinking certain foods in the last week.
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Eating behavior as measured by the Three Factor Eating Questionnaire
Eating behaviors will be assessed using the Three Factor Eating Questionnaire (TFEQ). The 21-item short-form will be used for the present study. The TFEQ measures three domains of eating behavior: 1) cognitive restraint, 2) uncontrolled eating, and 3) emotional eating.
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Physical activity as measured by the Stanford Leisure-Time Activity Categorical Item (L-Cat)
The L-Cat is a measure of physical activity. Individuals identify which descriptive category best describes their level of activity during leisure time in the last month. Descriptive categories range from inactive to very active.
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Patient self-efficacy for chronic disease coping as measured by Self-Efficacy for Managing Chronic Illness Scale
The 6-item Self-Efficacy for Managing Chronic Illness Scale will be used to assess participants' current confidence in their ability to prevent symptoms (e.g., pain, fatigue, distress) from interfering with life. Responses are on a 10-point scale from "not at all confident" (1) to "totally confident" (10).
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Patient self-efficacy for managing chronic conditions as measured by the PROMIS Self-Efficacy for Managing Symptoms Short Form
The 4-item PROMIS Self-Efficacy for Managing Symptoms will be used to assess participants' confidence in their ability to manage symptoms (e.g. during daily activities, in a public place). Items are scored on a 5-point Likert scale, with higher scores indicating greater confidence.
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Weight-related self-efficacy as measured by the Weight Efficacy Lifestyle Questionnaire
The Weight Efficacy Lifestyle Questionnaire is an 8-item measure of eating self-efficacy. Participants are asked to provide information about how certain they are that they can resist overeating in difficult situation (e.g., over the weekend, when tired, etc.). Response choices range from 0= "not at all confident" to 10= "very confident."
Measured: Baseline, Post-treatment (about 12-14 weeks after baseline)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2026
- Study start31 Aug 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast Cancer SurvivorshipStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Caroline Dorfman, PhD, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07426952
- Sponsor's protocol ID
- Pro00117620
- Acronym
- WeCan-Rural
- Status last verified
- Oct 2026
- First submitted
- 17 Feb 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No